Abstract
Alternating electric field therapy has been approved for glioblastoma (GBM). We have preclinical evidence for anticancer effects in GBM cell cultures and mouse xenografts with an oscillating magnetic field (OMF) generating device. Here we report OMF treatment of end-stage recurrent glioblastoma in a 53-year-old man who had undergone radical surgical excision and chemoradiotherapy, and experimental gene therapy for a left frontal tumor. He experienced tumor recurrence and progressive enlargement with leptomeningeal involvement. OMF for 5 weeks was well tolerated, with 31% reduction of contrast-enhanced tumor volume and reduction in abnormal T2-weighted Fluid-Attenuated Inversion Recovery volume. Tumor shrinkage appeared to correlate with treatment dose. These findings suggest a powerful new noninvasive therapy for glioblastoma.
Highlights
For glioblastoma (GBM), the most common malignant tumor of the brain in adults, treatment outcome remains dismal
A new FDA-approved treatment involving electric fields alternating at 200 kHz called OptuneTM therapy is available for recurrent GBM as monotherapy and in combination with temozolomide for newly diagnosed GBM [3, 4]
The findings of this study indicate that Oncomagnetic devicebased oscillating magnetic field (OMF) therapy is well tolerated by a patient who has endstage recurrent GBM with leptomeningeal involvement and has no other available effective treatment options
Summary
For glioblastoma (GBM), the most common malignant tumor of the brain in adults, treatment outcome remains dismal. A new FDA-approved treatment involving electric fields alternating at 200 kHz called OptuneTM therapy is available for recurrent GBM as monotherapy and in combination with temozolomide for newly diagnosed GBM [3, 4]. It is being tested in clinical trials for other cancers. Its hypothesized mechanism of action involves disruption of tubulin dimers, mitotic spindles, and cell division by electric field-induced dipole alignment and dielectrophoresis [5] It has a modest effect on survival, increasing median overall survival by 0.6 month in recurrent GBM [3], and in newly diagnosed GBM by 31% [4]. We report evidence of treatment response in the first patient to ever receive this therapy with an untreatable left frontal GBM, treated with a wearable Oncomagnetic device in an FDA-approved Expanded Access Program
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
